x min read

Stocks in the News: Lands' End, Inc. (NASDAQ:LE), ASML Holding NV (ADR) (NASDAQ:ASML), St. Jude Medical, Inc. (NYSE:STJ)

Stocks in the News: Lands' End, Inc. (NASDAQ:LE), ASML Holding NV (ADR) (NASDAQ:ASML), St. Jude Medical, Inc. (NYSE:STJ)
Written by
Joel Najarian
Published on
October 15, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Lands' End, Inc. (NASDAQ:LE) said Wednesday it named Josephine Linden, managing member and principal of Linden Global Strategies LLC, as the new chairman of the clothing-and-accessories retailer's board. Linden has been a member of LE's board since March 2014. She succeeds Elizabeth Darst Leykum, who had served as chairman since April and now becomes chair of the Nominating and Corporate Governance Committee. Since its March spinoff from Sears Holdings (SHLD), Lands' End, Inc. (NASDAQ:LE) has traded in a range of $25.35 to $47.87.ASML Holding NV (ADR) (NASDAQ:ASML) reported mixed financial results for Q3 ended Sept. 30, 2014, as earnings topped analysts' expectations while revenue fell short; it also provided sales guidance for Q4 and fiscal 2014. ADRs of the provider of advanced semiconductor equipment systems are down 1.29% at $92.37, with a 52-week range of $79.66 - $102.43. ASML Holding NV (ADR) (NASDAQ:ASML) posted Q3 earnings of EUR 244 million or EUR 0.56 per share ($308.96 million or $0.71 per share), compared with the prior-year period's EUR 193 million or EUR 0.44 per share ($244.38 million or $0.56 per share). Revenue was EUR 1.322 billion ($1.67 billion), up slightly from EUR 1.318 billion ($1.67 billion) in the same quarter last year.Analysts polled by Capital IQ were expecting EPS of EUR 0.53 ($0.67) on revenues of EUR 1.41 billion ($1.79 billion). For Q4, the company expects net sales of around EUR 1.3 billion ($1.65 billion), versus the Street view of EUR 1.19 billion ($1.51 billion). For the full year 2014, ASML says it remains on track to meet its forecast of at least EUR 5.6 billion ($7.09 billion) of net sales, versus the consensus of EUR 5.64 billion ($7.14 billion).St. Jude Medical, Inc. (NYSE:STJ) reported fiscal Q3 earnings that were just ahead of analysts' expectations while its guidance ranges for Q4 and the full year were about in line with the average Street view. St. Jude Medical, Inc. (NYSE:STJ) is trading in the lower half of the 52-week range between $53.51 and $71.90. The maker of cardiovascular medical devices said adjusted earnings in the quarter ended Sept. 27 rose 8% to $0.97 per share, topping the $0.96 average estimate from analysts polled by Capital IQ. Sales rose 3% to $1.37 billion compared to the $1.38 billion average estimate. Reported earnings fell to $238 million or $0.82 per share from $262 million or $0.90 per share.For Q4, St. Jude Medical said it expects sales between $1.39 billion and $1.47 billion compared to the $1.5 billion consensus estimate. It also expects consolidated adjusted net earnings between $1.02 to $1.04 per share compared to the $1.04 average estimate. For the full year, sales are seen at $5.57 billion to $5.65 billion compared to the $5.69 billion consensus while earnings are seen between $3.97 and $3.99 per share, vs. the $3.98 per share consensus.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.